On March 22, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for central nervous system cancers.
The version 4.2020 update features updates regarding treatment for brain metastases from ALK-positive non-small-cell lung cancer (NSCLC).
In the section labeled principles of brain and spinal cord tumor systemic therapy for brain metastases, lorlatinib was added as a category 2A recommendation for brain metastases from ALK-positive NSCLC.—Janelle Bradley